Alkermes (ALKS) Hits New Highs Amid Q1 Growth & Insider Sales

Font: Financial Modeling Prep  • Jun 04, 2026

Alkermes plc (NASDAQ: ALKS) Reaches New Highs as Investors Weigh Q1 Growth, Insider Sales and Valuation

• Alkermes plc (NASDAQ: ALKS) has shown strong stock performance recently, supported by positive Q1 financial results and growing investor interest in the company’s sleep medicine portfolio.
• At the same time, recent insider stock sales and valuation concerns suggest that investors may need to balance the company’s growth momentum with a closer look at risk and valuation.

Alkermes plc is a global biopharmaceutical company focused on developing medicines for central nervous system disorders. The company is increasingly expanding into sleep medicine, supported by its acquisition of Avadel Pharmaceuticals and the addition of LUMRYZ to its portfolio.

On June 4, 2026, Alkermes announced that it will present new data on alixorexton and LUMRYZ at SLEEP 2026, the annual meeting of the Associated Professional Sleep Societies. The company said 26 abstracts were accepted, including data related to narcolepsy and idiopathic hypersomnia.

The company’s recent stock performance has been strong. Alkermes shares recently traded near $43.38, reaching a new 52-week high and lifting the company’s market capitalization to approximately $7.21 billion. The move reflects improved investor confidence following the company’s latest financial results and progress in sleep medicine.

Alkermes reported total Q1 2026 revenues of $392.9 million, up 28.2% from $306.5 million in the same period last year. Proprietary product sales were supported by VIVITROL, ARISTADA, LYBALVI and the newly added LUMRYZ. However, the company also reported a GAAP net loss of $66.5 million, compared with net income of $22.5 million in the prior-year period. Diluted GAAP loss per share was $0.40, compared with diluted earnings per share of $0.13 a year earlier.

Recent insider activity has also attracted attention. On May 4, 2026, David Joseph Gaffin, Executive Vice President and Chief Legal Officer at Alkermes, sold 2,034 shares at $33.20 per share. More recently, Craig C. Hopkinson, Executive Vice President of Research & Development and Chief Medical Officer, sold 9,000 shares at a weighted average price of $41.67 per share on June 1, 2026. The transaction was made under a pre-arranged Rule 10b5-1 trading plan.

While insider sales can raise questions for investors, they do not always signal a negative outlook. Many insider transactions are tied to planned trading programs, tax planning or equity compensation management. Still, the timing of these sales may be worth watching as Alkermes stock trades near recent highs.

Valuation is another important factor. A recent GuruFocus analysis suggested that Alkermes was trading above its estimated GF Value of $30.79. With the stock now trading above $43, investors may need to decide whether the company’s stronger revenue growth, sleep medicine expansion and pipeline progress justify the higher valuation.

Overall, Alkermes remains a compelling biotech stock to watch. The company is benefiting from strong Q1 revenue growth, expanding sleep medicine opportunities and new clinical data presentations. However, the recent share price surge, insider selling activity and valuation concerns suggest that investors should approach the stock with balanced expectations.